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INTRODUCTION
Nicotinamide adenine dinucleotide (NAD) plays a critical role as a cofactor for oxidationreduction enzymes and histone deacetylase, and as a substrate for second messenger cADPribose production and poly ADP-ribosylation. Exposure to xenobiotic chemicals can result in altered total pyridine nucleotide levels, notably decreases in NAD caused by increased degradation or decreased biosynthesis of NAD; at the extreme, this can lead to apoptosis and cell death. The biosynthesis of NAD is under tight regulation by two routes in mammalian livers; de novo synthesis from Trp and the salvage pathway from nicotinic acid (see Fig. 1 ).
α-Amino-β-carboxymuconate-ε-semialdehyde (ACMS) generated from 3-hydroxyanthranilic acid, catalyzed by 3-hydroxyanthranilic acid oxygenase, is metabolized by α-amino-β-carboxymuconate-ε-semialdehyde decarboxylase (ACMSD) (E.C.4.1.1.45) or non-enzymatically to quinolinic acid, which is finally converted to NAD by quinolinate phosphoribosyltransferase (QAPRT) (E.C.2.4.2.19). ACMSD activity is found in the liver and kidney, although the activity in liver is much lower than that in kidney (Ikeda et al., 1965) . On the other hand, Ltryptophan 2, 3-dioxygenase (TDO) (E.C.1.13.11.11), the enzyme that initiates the Trp-NAD pathway, is only detectable in liver. Therefore, in mammals, liver is the sole organ having the complete Trp-NAD pathway, and hepatic ACMSD and QAPRT play critical roles in NAD biosynthesis, especially in the case of restricted niacin availability (Bender, 1983) .
Several steps of NAD biosynthesis from Trp have been reported to be up-or down-regulated by various factors including hormones (Mehler et al., 1958) , nutrients (Egashira et al., 2004; Sanada and Miyazaki, 1984) and drugs (Shin et al., 1999) , however the molecular mechanisms governing these changes are largely unknown. Clofibrate, a hypolipidaemic drug that stimulates peroxisome-proliferation and fatty acid β-oxidation, significantly increases hepatic NAD and total pyridine nucleotides levels in rats (Loo et al., 1995; Shin et al., 1999) . From the study of Trp fluxes in rat liver, the Trp-NAD pathway was increased by decreasing the flux via the glutarate pathway in hepatocytes prepared from rats fed a clofibrate diet (Shin et al., 1996) . The activities of key enzymes such as ACMSD and QAPRT changed in concert with the increase in hepatic NAD (Shin et al., 1999) . Peroxisome proliferators (PPs) such as 643, plasticizer This article has not been copyedited and formatted. The final version may differ from this version.
Molecular Pharmacology Fast Forward. Published on as DOI: 10.1124 at ASPET Journals on August 14, 2017 molpharm.aspetjournals.org Downloaded from MOL #26294 5 phthalate esters and dehydroepiandrosterone showed the same effect on ACMSD and QAPRT activities as clofibrate (Shin et al., 1999) . Since most of these drugs are known activators of peroxisome proliferator-activated receptor α (PPARα), a member of the nuclear receptor superfamily, the possibility exists that expression of the ACMSD and QAPRT genes are regulated by PPARα. PPARα is predominantly expressed in liver, heart, and kidney, which are tissues that carry out fatty acid oxidation.
Since the present study revealed that only ACMSD mRNA was down-regulated by activation of PPARα, it was examined in detail in the present study. The molecular mechanism for regulation of ACMSD by PPARα is not known. ACMSD is transcriptionally down-regulated by dietary polyunsaturated fatty acids (PUFA) (Egashira et al., 2004) . Expression of many other genes is also regulated by PUFA, for which PPARα-dependent or -independent mechanisms have been proposed (Jump, 2002; Jump et al., 1999; Pegorier et al., 2004) . Fatty acyl-CoAs, putative endogenous PPARα-ligands, are associated with hepatocyte nuclear factor 4α (HNF4α) (Hertz et al., 2001; Hostetler et al., 2005; Petrescu et al., 2002) , another member of the nuclear receptor superfamily that is expressed in the liver, kidney, intestine and pancreas (Sladec, 2001 ).
In mammalian liver, HNF4α functions as a homodimer and plays an important role in regulating genes involved in gluconeogenesis , ureogenesis (Rhee et al., 2003) , coagulation (Inoue et al., 2006) , amino acid synthesis (Kamiya et al., 2004) , and bile acid synthesis (Inoue et al., 2006) .
The current study was initiated to determine whether PPs affects Trp-NAD metabolism through altering the expression or activity of ACMSD and whether this regulation is mediated by PPARα and/or HNF4α. The results revealed that HNF4α directly activates the ACMSD gene by binding to a specific binding site located in the promoter, while PPARα reduces ACMSD expression by suppressing HNF4α protein levels.
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MATERIALS AND METHODS
Animals-PPARα-null mice and liver-specific HNF4α-null mice used in this study were as previously described (Hayhurst et al., 2001; Lee et al., 1995 Crude enzyme preparation and measurement of enzyme activity-A 25% liver homogenate was prepared using a polytron homogenizer in 50 mM potassium phosphate buffer (pH 7.0) containing 140 mM potassium chloride, 5 mM 2-mercaptoethanol, 1 mM dithiothreitol, 1 mM EDTA and 1 mM phenylmethanesulfonyl fluoride. The homogenate was centrifuged at 105, 000 x g for 1 h at 4 °C and the supernatant was used for the determination of ACMSD activity.
ACMSD activity was determined by the decrease in absorbance at 360 nm that monitors the decrease of ACMS produced from 3-hydroxyanthranilic acid. 3-Hydroxyanthranilic acid oxygenase was partially purified from acetone powder of mouse liver and used for the assay of ACMSD (Mehler, 1956 After washing, blots were exposed to a PhosphorImager screen,followed by visualization of signal using a Molecular Dynamics Storm 860 PhosphorImager system (Molecular Dynamics, Sunnyvale, CA). cDNAs used as a probe were amplified from a mouse hepatic cDNA library using gene-specific primers, which were then cloned into the pCR TOPOII vector (Invitrogen). Western blot analysis-Frozen livers were gently homogenized in a glass tube with a manual pestle, and nuclear and cytoplasmic extracts were prepared using NE-PER nuclear and cytoplasmic extraction reagents (Pierce, Rockford, IL) with the addition of proteinase inhibitors (Roche inhibitor cocktail set I and 1mM phenylmethylsulfonyl fluoride). Nuclear or cytoplasmic protein (15-50 µg) was subjected to SDS-PAGE (10-12.5%), followed by transfer to a polyvinylidene difluoride membrane (Amersham Biosciences). Determination of the transcription start site of ACMSD-The transcription start site of the mouse ACMSD gene was determined using mouse liver total RNA and the rapid amplification of 5'cDNA end (RACE) method with the GeneRacer Kit (Invitrogen). After first strand cDNA synthesis, PCR was performed with GeneRacer 5'primer and a reverse gene-specific primer, located within ACMSD exon 1. To generate a gene-specific RACE PCR product, nested PCR was performed with GeneRacer 5'nested primer and reverse gene-specific nested primer. The transcription start site was determined by sequencing cloned PCR products.
Construction of mouse ACMSD-luciferase reporter plasmids and site-directed mutagenesis-
The -685, -295, -220 and -52/+66 fragments from the transcription start site of the mouse ACMSD gene were amplified by PCR using a common ACMSD-specific 3' primer and a 5'primer and cloned into the luciferase reporter vector, pGL3 basic (Promega, Madison, WI).
Mutations were introduced into the HNF4α response element in the ACMSD-luciferase constructs (-685 and -295) using PCR-based, site-directed mutagenesis with QuickChange SiteDirected Mutagenesis Kit (Stratagene). All plasmids were confirmed by DNA sequencing. according to the manufacture's instruction. Luciferase activity was determined using Monolight 3010 Luminometer (Pharmingen), and the relative luciferase activity was expressed as a fold induction based on the activity of pGL3 basic.
Cell Culture and transient transfection assay-HepG2
Electrophoretic mobility shift assay-Nuclear extracts were prepared from livers of PPARα +/+ , PPARα -/-, HNF4α F/F and HNF4α L mice fed control or Wy-14, 643 diet. Nuclear extract (5 µg)
was preincubated at room temperature for 20 min in 20 mM HEPES-KOH, pH 7.9, 60 mM KCl, 0.3 mM MgCl 2 , 0.5 mM EDTA, 1.5 µg poly (dI-dC), 10 % glycerol and 1 mM dithiothreitol.
For competition experiments, a 50-fold excess of unlabelled oligonucleotide was added to the reaction mixture and incubation was continued for additional 20 min. 32 P end-labeled doublestranded oligonucleotide was then added and incubated at room temperature for 20 min. For super-shift analysis, 1 µg of anti-HNF4α antibody (Santa Cruz Biotechnology) was added to the reaction mixture. DNA-protein complexes were resolved on a 5% polyacrylamide gel in 0.5 × Tris borate/EDTA (TBE) at room temperature, and a dried gel was exposed to a PhosphorImager screen.
Statistical analysis-All values were expressed as the means ± SD. All data were analyzed by the unpaired Student's t test for significant differences. P<0.05 was considered significant.
This article has not been copyedited and formatted. The final version may differ from this version. TATA motif (TAAA) was located at -28 bp from the -74 bp transcription start site. Therefore the -74 bp from the translation start site was determined to be the major transcription initiation point of the mouse ACMSD gene (Fig. 3) .
HNF4α activates the mouse ACMSD promoter-Since ACMSD gene expression appears to be regulated by both HNF4α and PPARα, the ACMSD gene promoter sequence was analyzed for potential consensus binding sites for these transcription factors. Several putative binding sites were identified by MOTIF search (http://motif.genome.jp) with scores higher than 70 for HNF4α within -690 bp upstream of the mouse ACMSD gene transcription start site. While no high score PPARα binding sites were found, one low score site was found that partially overlapped with a -224 to -243 bp HNF4α binding site (Fig. 3) . Based on this information, several ACMSD promoter-luciferase reporter plasmids were constructed (Fig. 3, 4A) , and subjected to transient transfection analysis using human hepatocellular carcinoma-derived HepG2 cells that express endogenous HNF4α (Inoue et al., 2002) (Fig. 4B, upper panel) . The promoter activity of constructs with -295 bp and -685 bp fragments was significantly higher than those with the -52 bp or -220 bp fragment. These results suggested that one or more elements important for endogenous HNF4α (Inoue et al., 2002) were used for co-transfection analysis (Fig. 4C, upper panel). In both cells, co-transfection with an HNF4α expression plasmid significantly increased promoter activity of the -295 and -685 bp construct, but promoter activity of the -685 bp construct never exceeded the activity of the -295bp construct. Co-transfection of these constructs with an HNF1α expression vector had no effect on this promoter activity (data not shown). These results suggest that the putative HNF4α binding site at -224 to -243 bp identified by MOTIF may be responsible for the increased promoter activity.
Identification of HNF4α-binding site in the mouse ACMSD promoter-To prove that the putative HNF4α binding site located at -224 to -243 bp directly binds to HNF4α leading to the transcriptional activation of ACMSD gene, electrophoretic mobility shift assays (EMSAs) were performed (Fig. 5) . The protein in hepatic nuclear extracts from HNF4α F/F mice bound to the ACMSD-HNF4α binding sequence (Fig. 5B, lanes 3, 6) , and the shifted band corresponded in mobility to a band obtained when an HNF4α-consensus sequence was used as a probe ( (Fig.5D, lane 19) . Further, this band was not detected with extracts from HNF4α L mouse liver nuclei (Fig. 5B, lanes 9, 10) . Another putative HNF4α binding site with a score higher than 60 located between -685 and -220 bp of the ACMSD promoter, did not bind to HNF4α (data not shown).
In order to confirm that the -224 to -243 bp HNF4α binding site is functionally active, three different mutations were introduced in order to disrupt binding (Fig. 4A) , and EMSA ( Fig. 5C) and transfection assays (Fig. 4B, C) were performed. When examined by EMSA, these mutated probes did not appear bind to HNF4α (Fig. 5C , lanes 7, 9, 11), nor did they compete with the ACMSD-HNF4α probe by the addition of unlabeled competitor oligonucleotide probes (Fig. 5C , lane 4-6). However, a very faint band corresponding in mobility to the HNF4α Ab supershifted band (Fig. 5C , lane 2) was detected with the m1 oligo (Fig. 5C (Fig. 5D , lane 3, 6, 8 vs 1); this band was lost by the addition of a 50-fold excess of unlabeled oligonucleotide (Fig. 5D, lane 4, 7) or the ACMSD-HNF4 oligonucleotide (Fig. 5D, lane 5) .
Indeed, the ACOX-PPRE contains a sequence similar to the consensus HNF4α binding site (Fig.   5A ), thus accounting for this result (Sladek, 1994) . When ACMSD-HNF4α was used as a probe with HNF4α F/F nuclear extracts, a shifted band corresponding to HNF4α was lost with a 50-fold excess of unlabelled probes of ACMSD-HNF4α, HNF4α-consensus or ACOX-PPRE (Fig. 5D, lane 18, 19, 22, respectively), but not with ACMSD-PPRE or a consensus PPRE (Fig. 5D , lane 20, 21). Further, with the ACMSD-PPRE sequence as a probe, no bands were obtained with any nuclear extracts (Fig. 5D , lane 9-15). These results suggest that ACMSD-HNF4α sequence does not compete with ACMSD-PPRE sequence and that PPARα may not directly bind the ACMSD-PPRE site located -212 to -231 bp of the ACMSD promoter.
HNF4α protein level is decreased in livers from mice treated with Wy-14,643-To further
investigate the mechanism by which PPARα represses the transcription of ACMSD, the effect of Wy-14,643 and/or PPARα on the expression of HNF4α in mouse liver was studied by Western blot analysis (Fig. 6A) . The chromatin protein HMGB1 (Bustin, 2002) NAD from Trp in rodents. Alteration in ACMSD activity is correlated with hepatic NAD levels (Shin et al., 1999) , and the NAD metabolites N 1 -methylnicotinamide (NMNA), N 1 -methyl-4-pyridone-3-carboxamide (4-Py) and N 1 -methyl-2-pyridone-5-carboxamide (2-Py) excreted in urine as biomarkers (Delaney et al., 2005) . ACMSD activity was reported to be down-regulated by dietary PUFA (Egashira et al., 2004) , low protein and peroxisome proliferators (Loo et al., 1995; Shin et al., 1999) , and up-regulated by glucocorticoids , high protein diets and in streptozotocin-induced diabetic rats .
The mechanisms mediating these activity changes are not known.
In the current study by using PPARα-null or liver-specific HNF4α-null mice, the expression of ACMSD was found to be under positive and negative regulation of HNF4α and PPARα, respectively. ACMSD mRNA is suppressed in wild-type mice and not in PPARα-null mice administered the ligand Wy-14,643 indicating that PPARα attenuates ACMSD gene expression.
Levels of ACMSD mRNA and activity are markedly lower in mice lacking hepatic expression of HNF4α revealing that HNF4α controls constitutive expression of the gene. Indeed, a functional HNF4α binding site was located in the ACMSD gene promoter that is responsible for the increased promoter activity by HNF4α as assessed by reporter gene transfection studies.
Activation of PPARα also results in post-transcriptional suppression of HNF4α protein levels that correlates with decreased expression of ACMSD. However, ACMSD expression is also suppressed in HNF4α L mice fed Wy-14,643, suggesting that there may be another indirect mechanism by which this gene is suppressed by PPARα. HNF4α is constitutively expressed in liver and is active in the absence of exogenous ligand while PPARα is a ligand-activated transcription factor. HNF4α and PPARα share a similar DR1 (hexanucleotide direct repeat with a one base spacer) consensus binding sequences (Hertz et al., 1998; Sladek, 1994) . Indeed, a DR1 was found in the mouse ACMSD promoter, and activation of the promoter was mediated by
HNF4α binding similar to other HNF4α target genes (Rajas et al., 2002) . DR1 elements are quite promiscuous, thus allowing binding of other transcription factors including HNF4α, This article has not been copyedited and formatted. The final version may differ from this version. PPARα/RXRα, RXRα homodimers, RARα/RXRα heterodimers, and COUP-TFI and II (Nakshatri and Bhat-Nakshatri, 1998) , suggesting that these factors potentially could compete for binding to specific DR1 elements. Actually, competitive binding of HNF4α and PPARα/RXRα to DR1 elements as a mechanism for modulating transcriptional activation of target genes has been proposed (Hertz et al., 1995; Hertz et al., 1996; Marrapodi and Chiang, 2000) . For example, HNF4α was reported to bind to the ACOX-PPRE (Sladek, 1994) and, in HepG2 cells, the apolipoprotein C-III (apoC-III) promoter activity was affected by hypolipidemic drugs (Hertz et al., 1995) . PPARα and RXRα specifically counteracted HNF4α-activated transcription rather than inhibiting basal transcription of apoC-III. This result is similar to what was observed for the ACMSD gene in the current study. By EMSA using in vitro translated or COS cells expressed transcription factors, HNF4α and PPARα/RXRα heterodimers bound strongly to the C3P elements (Hertz et al., 1995) , previously shown to be the binding site of nuclear proteins to the rat and human apoC-III gene promoter (Mietus-Snyder et al., 1992) . However, the binding of PPARα/RXRα to the ACMSD gene HNF4α binding site was not observed in the current studies. These data indicate that PPARα reduces ACMSD gene expression indirectly through lowering cellular contents of HNF4α protein. However, it should be noted that a small but significant suppression of residual ACMSD activity was also found in the HNF4α L liver fed wy-14,643, suggesting the possibility of another mechanism for attenuation of expression in this mouse model that is independent of HNF4α protein. In another study, cholesterol 7α-hydroxylase (CYP7A1) was reduced by treatment with fibrates, and the reporter activity of a human CYP7A1-luciferase construct was down-regulated by Wy-14,643 (Marrapodi and Chiang, 2000) . Similar to the current results with ACMSD, no direct binding of in vitro synthesized PPARα/RXRα heterodimer to the DR1 element of this gene was detected by EMSA.
Therefore, it was suggested that attenuation of the transactivation of this gene is due to altered availability of HNF4α in the presence of PPARα and its ligand (Marrapodi and Chiang, 2000) .
The effects of fibrates on HNF4α protein were not examined in this study.
The current finding, that Wy-14,643 treatment resulted in a PPARα-dependent suppression of HNF4α protein levels is similar to that observed in HepG2 cells treated with Wy-14, 643 (Marrapodi and Chiang, 2000) . Of interest, activation of AMP-activated protein kinase
This article has not been copyedited and formatted. The final version may differ from this version. HNF4α protein levels and consequently, the expression of HNF4α target genes was downregulated, but HNF4α mRNA was unchanged (Leclerc et al., 2001) . Indeed, in the liver of PPAR +/+ and HNF4α F/F mice treated with Wy-14,643, expression of HNF4α target genes encoding OTC, L-PK and ApoC-III were also down-regulated. Phosphorylation was suggested to be one of regulatory mechanisms of HNF4α transactivation activity. HNF4α can be phosphorylated by PKA (Viollet et al., 1997) , ERK (Reddy et al., 1999) , AMPK (Hong et al., 2003; Leclerc et al., 2001 ) and JNK1 (Jahan and Chiang, 2005) , and phosphorylation suppresses the DNA-binding affinity and trans-activation of HNF4α. Modulation of kinase activity can also alter target gene expression by altering HNF4α protein levels (Hong et al., 2003; Jahan and Chiang, 2005; Leclerc et al., 2001; Reddy et al., 1999) . Inhibition of ERK increased HNF4α mRNA and protein level (Reddy et al., 1999 ) while activation of AMPK was shown to promote degradation of HNF4α protein without changing HNF4α mRNA expression (Hong et al., 2003; Leclerc et al., 2001) . However, preliminary studies in vivo revealed that activation of PPARα by Wy-14,643 had no effect on AMPK activity (date now shown). In any case, it still remains to be determined whether phosphorylation is the underlying mechanism of the reduced HNF4α protein level and ACMSD expression in Wy-14,643-treated mouse liver, and which kinase is responsible. Nevertheless, it is interesting that the activation of PPARα represses HNF4α protein expression as well as transcription of its target genes suggesting that some phenotypes result from PPARα activation in liver may be through HNF4α repression. Given that PPARα target gene expression was induced in HNF4α-null mouse liver (Hayhurst et al., 2001) , it is of interest to investigate cross-talk between PPARα and HNF4α in normal and disease states.
In conclusion, the role of transcriptional factors, HNF4α and PPARα in the biosynthesis of Trp-NAD was examined. The ACMSD promoter activity was found to be under direct transcriptional regulation by HNF4α. Wy-14,643 activation of PPARα indirectly results in suppression of HNF4α protein levels, leading to the negative regulation of ACMSD activity.
These results will provide a better understanding of the Trp-NAD pathway and NAD homeostasis.
